Royalty Pharma
RPRX
RPRX
212 hedge funds and large institutions have $10.8B invested in Royalty Pharma in 2021 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 85 increasing their positions, 56 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
4.44% more ownership
Funds ownership: 59.3% → 63.74% (+4.4%)
2% more call options, than puts
Call options by funds: $46.5M | Put options by funds: $45.7M
5% less capital invested
Capital invested by funds: $11.4B → $10.8B (-$608M)
Holders
212
Holding in Top 10
11
Calls
$46.5M
Puts
$45.7M
Top Buyers
| 1 | +$1.06B | |
| 2 | +$902M | |
| 3 | +$201M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$131M |
| 5 |
State Street
Boston,
Massachusetts
|
+$102M |
Top Sellers
| 1 | -$612M | |
| 2 | -$557M | |
| 3 | -$173M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$160M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$113M |